DSpace Repository

Prevalence and Trajectories of Post-COVID-19 Neurological Manifestations: A Systematic Review and Meta-Analysis

Show simple item record

dc.contributor.author Giussani, Giorgia
dc.contributor.author Westenberg, Érica
dc.contributor.author García-Azorín, David
dc.contributor.author Bianchi, Elisa
dc.contributor.author Yusof Khan, Abdul Hanif Khan
dc.contributor.author Allegri, Ricardo Francisco
dc.contributor.author Atalar, Arife Çimen
dc.contributor.author Baykan, Betul
dc.contributor.author Crivelli, Lucía
dc.contributor.author Fornari, Arianna
dc.contributor.author Frontera, Jennifer
dc.contributor.author Guekht, Alla
dc.contributor.author Helbok, Raimund
dc.contributor.author Kee Hoo, Fan
dc.contributor.author Kivipelto, Miia
dc.contributor.author Leonardi, Matilde
dc.contributor.author López Rocha, Ana Sabsil
dc.contributor.author Mangialasche, Francesca
dc.contributor.author Marcassoli, Alessia
dc.contributor.author Global COVID-19 Neuro Research Coalition
dc.date.accessioned 2024-04-15T13:22:05Z
dc.date.available 2024-04-15T13:22:05Z
dc.date.issued 2024-01-25
dc.identifier.citation Giussani G, Westenberg E, Garcia-Azorin D, Bianchi E, Yusof Khan AHK, Allegri RF, Atalar AÇ, Baykan B, Crivelli L, Fornari A, Frontera JA, Guekht A, Helbok R, Hoo FK, Kivipelto M, Leonardi M, Lopez Rocha AS, Mangialasche F, Marcassoli A, Özdag Acarli AN, Ozge A, Prasad K, Prasad M, Sviatskaia E, Thakur K, Vogrig A, Leone M, Winkler AS; Global COVID-19 Neuro Research Coalition. Prevalence and Trajectories of Post-COVID-19 Neurological Manifestations: A Systematic Review and Meta-Analysis. Neuroepidemiology. 2024;58(2):120-133. doi: 10.1159/000536352. Epub 2024 Jan 25. es_ES
dc.identifier.uri https://doi.org/10.1159/000536352
dc.identifier.uri https://repositorio.fleni.org.ar/xmlui/handle/123456789/1073
dc.description.abstract Introduction: The aim of this systematic review and meta-analysis was to evaluate the prevalence of thirteen neurological manifestations in people affected by COVID-19 during the acute phase and at 3, 6, 9 and 12-month follow-up time points. Methods: The study protocol was registered with PROSPERO (CRD42022325505). MEDLINE (PubMed), Embase, and the Cochrane Library were used as information sources. Eligible studies included original articles of cohort studies, case-control studies, cross-sectional studies, and case series with ≥5 subjects that reported the prevalence and type of neurological manifestations, with a minimum follow-up of 3 months after the acute phase of COVID-19 disease. Two independent reviewers screened studies from January 1, 2020, to June 16, 2022. The following manifestations were assessed: neuromuscular disorders, encephalopathy/altered mental status/delirium, movement disorders, dysautonomia, cerebrovascular disorders, cognitive impairment/dementia, sleep disorders, seizures, syncope/transient loss of consciousness, fatigue, gait disturbances, anosmia/hyposmia, and headache. The pooled prevalence and their 95% confidence intervals were calculated at the six pre-specified times. Results: 126 of 6,565 screened studies fulfilled the eligibility criteria, accounting for 1,542,300 subjects with COVID-19 disease. Of these, four studies only reported data on neurological conditions other than the 13 selected. The neurological disorders with the highest pooled prevalence estimates (per 100 subjects) during the acute phase of COVID-19 were anosmia/hyposmia, fatigue, headache, encephalopathy, cognitive impairment, and cerebrovascular disease. At 3-month follow-up, the pooled prevalence of fatigue, cognitive impairment, and sleep disorders was still 20% and higher. At six- and 9-month follow-up, there was a tendency for fatigue, cognitive impairment, sleep disorders, anosmia/hyposmia, and headache to further increase in prevalence. At 12-month follow-up, prevalence estimates decreased but remained high for some disorders, such as fatigue and anosmia/hyposmia. Other neurological disorders had a more fluctuating occurrence. Discussion: Neurological manifestations were prevalent during the acute phase of COVID-19 and over the 1-year follow-up period, with the highest overall prevalence estimates for fatigue, cognitive impairment, sleep disorders, anosmia/hyposmia, and headache. There was a downward trend over time, suggesting that neurological manifestations in the early post-COVID-19 phase may be long-lasting but not permanent. However, especially for the 12-month follow-up time point, more robust data are needed to confirm this trend. es_ES
dc.language.iso eng es_ES
dc.publisher Karger es_ES
dc.rights info:eu-repo/semantics/openAccess
dc.subject COVID-19 es_ES
dc.subject Manifestaciones Neurológicas es_ES
dc.subject Neurologic Manifestations es_ES
dc.title Prevalence and Trajectories of Post-COVID-19 Neurological Manifestations: A Systematic Review and Meta-Analysis es_ES
dc.type info:eu-repo/semantics/article es_ES
dc.type info:eu-repo/semantics/publishedVersion
dc.description.fil Fil: Allegri, Ricardo Francisco. Fleni. Departamento de Neurología. Servicio de Neurología Cognitiva, Neuropsicología y Neuropsiquiatría; Argentina.
dc.description.fil Fil: Crivelli, Lucía. Fleni. Departamento de Neurología. Servicio de Neurología Cognitiva, Neuropsicología y Neuropsiquiatría; Argentina.
dc.relation.ispartofVOLUME 58
dc.relation.ispartofNUMBER 2
dc.relation.ispartofPAGINATION 120-133.
dc.relation.ispartofCOUNTRY Estados Unidos
dc.relation.ispartofCITY Nueva York
dc.relation.ispartofTITLE Neuroepidemiology
dc.relation.ispartofISSN 1423-0208
dc.type.snrd info:ar-repo/semantics/artículo es_ES


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Browse

My Account

Statistics